Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pernix Therapeutics Holdings Inc Lowers FY 2013 Revenue Guidance; Updates On Q4 2013 Revenue Guidance


Tuesday, 12 Nov 2013 08:30am EST 

Pernix Therapeutics Holdings Inc announced that for fiscal 2013, it expects revenue of $80.0 million, from the previous range of $90.0-$100.0 million. For the fourth quarter of 2013, it expects net revenue to be approximately $22.0 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $94 million for fiscal 2013. 

Company Quote

7.64
-0.22 -2.80%
29 Sep 2014